Pfizer: Time to Invest?
Related Articles
Editor’s note: Is it time to consider Pfizer as a serious investment? Let it slide lower first, says Charles Delvalle.
GlaxoSmithKline added to Pfizer’s woes today with a new assault on the anti-smoking pill market, previously dominated by Pfizer’s Chantix. Chantix has been losing ground since January, when US regulators warned about suicide risks connected with the drug.
Ride or Slide: Pfizer
Charles Delvalle
I typically don’t cover pharmaceutical stocks because, in all honesty, the sector bores me a little. Something about hormones and cells just puts me to sleep. But I couldn’t pass up the one Frank Y. wanted me to cover…
I liked your comments on GE.
Is Pfizer in the same position, is it a falling knife, or has it bottomed?
Pfizer – the maker of the ever-popular little blue pill. Describing them as a falling knife, though, is extremely appropriate. When you look at their chart, you should stretch it out as far as possible. That’s because this company is trading lower than any point in the last ten years.
But why?
Earnings dropped 17% last quarter and revenue dropped 5%. Why? They lost market exclusivity for Zoloft and Norvasc. This loss comes after they reduced their workforce by 10,000 people.
But the company is trying to right the ship. Revenues dropped only slightly, they’re buying back stock (last year they bought $10 billion) and they increased their dividend.
With all that said, I think Pfizer is a strong company, has a few promising drugs in phase 3 studies and should do well in the future. Unfortunately, the uncertainty all of these changes bring is forcing their share price lower.
Right now, the best thing to do is let Pfizer (PFE) slide for a while. In the next year, they could be an amazing buy.
Source: Ride or Slide: Pfizer (PFE)
| Email Address: | Subscribe |
NO-SPAM PLEDGE: We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from Investor's Daily Edge with a few clicks.
Related Articles
Tags: Charles Devalle, investing in biotech, US stocksAbout the Author
Charles Delvalle is a self-taught market-timing professional and value analyst who uses a combination of technical indicators and fundamental research to achieve consistent gains on stocks, commodities and options.
Charles is also a staunch contrarian and takes pride in finding undervalued sectors and discovering great companies on the cheap. He questions government reports and the status quo. In addition to swing trading options, Charles is also Co-Editor of the monthly advisory service - INCOME.
Investor's Daily Edge is a free investment e-letter delivered every day before the market opens. In each issue you'll receive clear recommendations and practical strategies for protecting your portfolio and multiplying your money, whether the market is rising or falling.